Advertisement
ALT vs INDP
Which Stock Would AI Choose? Altimmune (ALT) vs. Indaptus Therapeutics (INDP) Stock Comparison
1. Key Takeaways
- ALT is a late clinical-stage biopharmaceutical company advancing pemvidutide through a Phase 3 trial, while INDP is a clinical-stage immunotherapy developer that has paused its lead Decoy20 program and is evaluating strategic alternatives.
- Altimmune holds a materially stronger balance sheet — roughly $519 million in cash and short-term investments with runway into 2029 — versus Indaptus's approximately $11.6 million.
- ALT carries active analyst coverage with a "Strong Buy" consensus, whereas INDP currently has no formal analyst coverage, reflecting divergent market positioning.
- Both stocks have experienced significant drawdowns over the past year, and INDP's profile includes higher dilution risk after a 1-for-28 reverse stock split and multiple private placements.
- Relative performance favors neither name outright: ALT offers a defined late-stage catalyst path, while INDP presents a higher-risk, strategic-restructuring story.
- For more context on each name's developments and intraday behavior, explore ALT Major News, ALT Today's Price Move, INDP Major News, and INDP Today's Price Move.
- To see how automated systems are positioning across these and other tickers, visit Trending AI Robots.
2. Introduction
Altimmune (ALT) and Indaptus Therapeutics (INDP) are both pre-revenue, small-cap biotechnology companies, yet they occupy very different positions on the clinical-development and capital continuum. This stock comparison is most relevant to growth-oriented traders and investors who are comfortable with biotechnology's binary, catalyst-driven risk profile. Altimmune is advancing a late-stage liver-disease pipeline with a funded path toward a Phase 3 readout, while Indaptus is navigating a strategic review after stepping back from its lead clinical program. Understanding how their relative performance, balance sheets, and catalysts differ can help readers assess which market positioning better aligns with their own risk tolerance and time horizon.
2. ALT Overview and Recent Performance
Altimmune is a late clinical-stage biopharmaceutical company focused on serious liver diseases. Its lead candidate, pemvidutide, is an investigational dual glucagon/GLP-1 (glucagon-like peptide-1) receptor agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The U.S. Food and Drug Administration (FDA) has granted pemvidutide Breakthrough Therapy Designation for MASH, and the company has initiated its global Phase 3 PERFORMA registrational study.
In recent market activity, ALT has traded well below its 52-week highs, with a year-to-date decline against a backdrop of sector-wide biotech weakness. Sentiment has been shaped by a mix of positive clinical updates — including Phase 2 AUD data that met its primary endpoint — and broader pressure on small-cap, pre-revenue names. The company's strengthened cash position, reported at roughly $519 million with a runway into 2029, provides a degree of financial cushion that is uncommon among peers of its size. Analyst coverage remains constructive, with a consensus "Strong Buy" rating, though the stock's drawdown highlights the market's sensitivity to execution and financing events.
2. INDP Overview and Recent Performance
Indaptus Therapeutics is a clinical-stage biotechnology company developing immunotherapies based on its patented Decoy platform, which uses attenuated and killed, non-pathogenic bacteria to activate both innate and adaptive immunity. Its lead candidate, Decoy20, was studied in oncology. In recent quarters, however, the company discontinued further enrollment in its Decoy20 combination study, leaving it with no active clinical development programs, and it has since been evaluating strategic alternatives for the program and its broader operations.
INDP has experienced pronounced volatility over the past year, trading within a wide 52-week range and declining sharply from earlier highs. The company completed a 1-for-28 reverse stock split and has relied on private placements — including a roughly $12 million financing in June 2026 — to support its balance sheet. With approximately $11.6 million in cash and short-term investments, its financial runway is considerably shorter than Altimmune's, and it carries no formal analyst coverage. Recent developments, such as an early-stage research collaboration focused on neurological disorders and sleep, signal a pivot in strategic direction rather than a near-term commercial catalyst.
2. Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of automated trading systems drawn from Tickeron's broader library of hundreds of AI trading bots, which collectively monitor and trade thousands of different tickers. Rather than showcasing every available bot, this section surfaces only those best suited to current market conditions. The featured bots span a wide variety of trading styles, strategies, timeframes, performance statistics, and sets of tickers, allowing users to evaluate options aligned with different risk profiles — from short-term momentum approaches to longer-horizon trend-following models. For traders comparing names such as ALT and INDP, exploring these automated systems can offer an additional, data-driven perspective on relative momentum and positioning. To review the currently featured bots, visit Trending AI Robots.
2. Head-to-Head Comparison
The most fundamental contrast between these two stocks is stage of development. Altimmune is executing a late-stage clinical plan with a defined catalyst timeline — the Phase 3 PERFORMA study in MASH plus ongoing AUD and ALD trials — backed by substantial cash reserves. Indaptus, by contrast, has moved away from active clinical development and is focused on strategic alternatives, making its outlook more dependent on corporate actions and future financing than on near-term data readouts.
From a growth-driver perspective, ALT's potential is tied to pemvidutide's clinical and regulatory progress in large, competitive therapeutic markets. INDP's potential is currently less defined, hinging on whether management can identify and fund a viable strategic path. On risk factors, both face binary clinical and financing risk, but INDP's shorter runway and history of dilutive capital raises — including a reverse split — represent a more acute capital-structure risk. Sector exposure is broadly similar (both are healthcare/biotechnology), yet market sentiment diverges: ALT retains institutional sell-side coverage and a bullish consensus, while INDP trades as a thinly covered micro-cap with wider price swings. In relative performance terms, both names have lagged, but their risk profiles place them in very different categories of the biotech universe.
2. Tickeron AI Verdict
Based on observable factors — trend consistency, capital stability, catalyst visibility, and relative positioning — Tickeron's AI would likely favor Altimmune over Indaptus in the current environment. ALT's stronger balance sheet, active late-stage program, and retained analyst coverage suggest a more stable, catalyst-driven setup, whereas INDP's paused clinical development, shorter runway, and strategic uncertainty introduce higher variability into its forward path. This assessment is probabilistic rather than definitive: both stocks carry material risk, and automated systems may revise their stance as new data, financing events, and price action unfold.
2. Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALT is a Hold and INDP is a Hold.
ALT in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 10, 2026
ALT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 37 of 42 cases where ALT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ALT's RSI Oscillator exited the oversold zone, 37 of 45 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 70 cases where ALT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for ALT just turned positive on November 02, 2026. Looking at past instances where ALT's MACD turned positive, the stock continued to rise in 36 of 46 cases over the following month. The odds of a continued upward trend are 78%.
Following a +7.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALT advanced for three days, in 204 of 256 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALT as a result. In 79 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for ALT entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. ALT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.853) is normal, around the industry mean (3.498). P/E Ratio (-2.737) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (1678.863) settles around the average of (130.981) among similar stocks. ALT's P/S Ratio (10000.000) is very high in comparison to the industry average of (440.869).
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
INDP saw its Stochastic Oscillator recovers from the overbought zone
The Stochastic Oscillator for INDP moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 41 similar instances where the indicator exited the overbought zone. In 39 of the 41 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on INDP as a result. In 87 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for INDP turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 48 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INDP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
Bullish Trend Analysis
The 50-day moving average for INDP moved above the 200-day moving average on October 22, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +1.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where INDP advanced for three days, in 167 of 214 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
INDP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 66 of 90 cases where INDP Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. INDP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 83 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (38.898) is normal, around the industry mean (3.498). P/E Ratio (-0.933) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INDP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
ALT | INDP | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 7 | 84 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 94 Overvalued | 90 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 96 | 100 | |
PRICE GROWTH RATING 1..100 | 83 | 34 | |
P/E GROWTH RATING 1..100 | 16 | 83 | |
SEASONALITY SCORE 1..100 | 75 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
INDP's Valuation (90) in the null industry is in the same range as ALT (94) in the Miscellaneous Commercial Services industry. This means that INDP’s stock grew similarly to ALT’s over the last 12 months.
INDP's Profit vs Risk Rating (100) in the null industry is in the same range as ALT (100) in the Miscellaneous Commercial Services industry. This means that INDP’s stock grew similarly to ALT’s over the last 12 months.
ALT's SMR Rating (96) in the Miscellaneous Commercial Services industry is in the same range as INDP (100) in the null industry. This means that ALT’s stock grew similarly to INDP’s over the last 12 months.
INDP's Price Growth Rating (34) in the null industry is somewhat better than the same rating for ALT (83) in the Miscellaneous Commercial Services industry. This means that INDP’s stock grew somewhat faster than ALT’s over the last 12 months.
ALT's P/E Growth Rating (16) in the Miscellaneous Commercial Services industry is significantly better than the same rating for INDP (83) in the null industry. This means that ALT’s stock grew significantly faster than INDP’s over the last 12 months.
| ALT | INDP | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 82% | N/A |
| Stochastic ODDS (%) | 1 day ago 77% | 1 day ago 90% |
| Momentum ODDS (%) | 1 day ago 88% | 1 day ago 90% |
| MACD ODDS (%) | 1 day ago 78% | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 87% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 86% | 1 day ago 77% |
| Advances ODDS (%) | 3 days ago 80% | 14 days ago 78% |
| Declines ODDS (%) | 1 day ago 88% | 2 days ago 89% |
| BollingerBands ODDS (%) | 1 day ago 88% | 1 day ago 83% |
| Aroon ODDS (%) | 1 day ago 89% | 1 day ago 73% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALT’s FA Score shows that 1 FA rating(s) are green while INDP’s FA Score has 0 green FA rating(s).
- ALT’s FA Score: 1 green, 4 red.
- INDP’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALT’s TA Score shows that 5 TA indicator(s) are bullish while INDP’s TA Score has 4 bullish TA indicator(s).
- ALT’s TA Score: 5 bullish, 3 bearish.
- INDP’s TA Score: 4 bullish, 4 bearish.
Price Growth
ALT (@Biotechnology) experienced а -8.96% price change this week, while INDP (@Biotechnology) price change was -2.73% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.
Reported Earning Dates
ALT is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (-0.49% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ALT and
Correlation & Price change
A.I.dvisor indicates that over the last year, ALT has been loosely correlated with OGEN. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ALT jumps, then OGEN could also see price increases.
| Ticker / NAME | Correlation To ALT | 1D Price Change % | ||
|---|---|---|---|---|
| ALT | 100% | -0.52% | ||
| OGEN - ALT | 54% Loosely correlated | -0.58% | ||
| DNLI - ALT | 45% Loosely correlated | -0.60% | ||
| EDIT - ALT | 45% Loosely correlated | -4.99% | ||
| FLNA - ALT | 45% Loosely correlated | -0.04% | ||
| INDP - ALT | 45% Loosely correlated | +10.69% | ||
More | ||||
INDP and
Correlation & Price change
A.I.dvisor indicates that over the last year, INDP has been loosely correlated with VERU. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if INDP jumps, then VERU could also see price increases.
| Ticker / NAME | Correlation To INDP | 1D Price Change % | ||
|---|---|---|---|---|
| INDP | 100% | +10.69% | ||
| VERU - INDP | 48% Loosely correlated | +0.94% | ||
| ALT - INDP | 45% Loosely correlated | -0.52% | ||
| NBP - INDP | 38% Loosely correlated | +0.10% | ||
| VKTX - INDP | 30% Poorly correlated | -0.77% | ||
| ORMP - INDP | 29% Poorly correlated | +4.03% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| CRYPTO / NAME | Price $ | Chg $ | Chg % |
| NFP.X | 0.000212 | 0.000082 | +62.46% |
| NFPrompt cryptocurrency | |||
| GAL.X | 0.790902 | 0.007807 | +1.00% |
| Galatasaray Fan Token cryptocurrency | |||
| HBAR.X | 0.065461 | -0.000111 | -0.17% |
| Hedera cryptocurrency | |||
| USDP.X | 0.993555 | -0.003286 | -0.33% |
| Pax Dollar cryptocurrency | |||
| ZEN.X | 4.805079 | -0.138205 | -2.80% |
| Horizen cryptocurrency | |||